Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC.FENC · Entity 5601 | CHIEF FINANCIAL OFFICER | October 12, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FENNEC PHARMACEUTICALS INC.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common sharesSEC Table I · non-derivative | Direct | 246,855 |
Reported balance
After 2026-10-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-12 · Grant · Acquired 3,846 · Balance 246,855 F1: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 13, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 3,846 | $5.53 | $21,268.38 |
DisclosureSEC source: 0001468308-26-000034 · form4-10132026_041001.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,855 F1 · security: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 00:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000032 · form4-10012026_041001.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,009 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 00:09 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000030 · form4-09012026_120910.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,306 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 21:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 21,928 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001468308-26-000028 · form4-08282026_090813.xml · derivative · entry 3 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 779,330 Underlying: Common Shares · 21,928 shares Expires 2027-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027. Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 21:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 21,928 | $5.10 | $111,832.80 |
DisclosureSEC source: 0001468308-26-000028 · form4-08282026_090813.xml · nonDerivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 21:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 75,000 | $11.78 | $883,500.00 |
DisclosureSEC source: 0001468308-26-000028 · form4-08282026_090813.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,675 F1 · security: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). A portion of the sales proceeds from this transaction will be used by the reporting person to pay tax obligations of the reporting person. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000026 · form4-08032026_040801.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,675 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:35 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000024 · form4-07012026_080710.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,972 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. Read SEC document |
| May 31, 2026 Filed Jun 1, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000022 · form4-06012026_040601.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,269 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000020 · form4-05012026_040501.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 120,000 | $5.77 Strike: $5.77 | $692,400.00 |
DisclosureSEC source: 0001468308-26-000018 · form4-04022026_040401.xml · derivative · entry 4 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 921,045 Underlying: Options · 120,000 shares Expires 2036-03-31 F4 · security: On March 31, 2026, granted incentive stock options to purchase 120,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F5 · derivative.exercise_date: One-third of the shares subject to this option may be exercised as of March 31, 2027 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of March 31, 2029, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 2,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000018 · form4-04022026_040401.xml · nonDerivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 14,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000018 · form4-04022026_040401.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents settlement of PSUs that vested on March 31, 2026. Read SEC document |
| March 28, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 12,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000018 · form4-04022026_040401.xml · nonDerivative · entry 3 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| March 26, 2026 Filed Mar 26, 2026 20:30 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 13,072 | $5.10 Strike: $5.10 | $66,667.20 |
DisclosureSEC source: 0001468308-26-000016 · form4-03262026_080309.xml · derivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 801,045 Underlying: Options · 13,072 shares Expires 2027-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $5.10 and an expiration date of June 27, 2027. Read SEC document |
| March 26, 2026 Filed Mar 26, 2026 20:30 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 13,072 | $5.10 | $66,667.20 |
DisclosureSEC source: 0001468308-26-000016 · form4-03262026_080309.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $5.10 and an expiration date of June 27, 2027. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000014 · form4-03032026_040303.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,584 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 23:43 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 2,450 | $4.08 Strike: $4.08 | $9,996.00 |
DisclosureSEC source: 0001468308-26-000012 · form4-02192026_110240.xml · derivative · entry 3 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 814,117 Underlying: Options · 2,450 shares Expires 2031-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $4.08 and an expiration date of December 20, 2031. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 23:43 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 27,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000012 · form4-02192026_110240.xml · nonDerivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,393 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents settlement of PSUs that vested on February 18, 2026. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 23:43 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 2,450 | $4.08 | $9,996.00 |
DisclosureSEC source: 0001468308-26-000012 · form4-02192026_110240.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $4.08 and an expiration date of December 20, 2031. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000010 · form4-02022026_040201.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,658 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 21:56 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 10,000 | $2.45 Strike: $2.45 | $24,500.00 |
DisclosureSEC source: 0001468308-26-000008 · form4-01232026_090158.xml · derivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 816,567 Underlying: Options · 10,000 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 21:56 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 10,000 | $2.45 | $24,500.00 |
DisclosureSEC source: 0001468308-26-000008 · form4-01232026_090158.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026. Read SEC document |
| January 15, 2026 Filed Jan 15, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 10,000 | $2.45 Strike: $2.45 | $24,500.00 |
DisclosureSEC source: 0001468308-26-000006 · form4-01152026_040101.xml · derivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 826,567 Underlying: Options · 10,000 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026. Read SEC document |
| January 15, 2026 Filed Jan 15, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 10,000 | $2.45 | $24,500.00 |
DisclosureSEC source: 0001468308-26-000006 · form4-01152026_040101.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026. Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 21:28 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 14,184 | $2.45 Strike: $2.45 | $34,750.80 |
DisclosureSEC source: 0001468308-26-000004 · form4-01072026_090120.xml · derivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 836,567 Underlying: Options · 14,184 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026. Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 21:28 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 14,184 | $2.45 | $34,750.80 |
DisclosureSEC source: 0001468308-26-000004 · form4-01072026_090120.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000002 · form4-01052026_040102.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,916 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 23:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 2,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-25-000008 · form4-12022025_061205.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,534 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| October 31, 2025 Filed Nov 3, 2025 22:32 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 2,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-25-000007 · form4-11032025_101147.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,104 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:10 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 2,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-25-000005 · form4-10012025_041001.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,674 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| August 31, 2025 Filed Sep 2, 2025 20:10 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 2,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023396 · form4-09022025_040903.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,244 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| July 31, 2025 Filed Aug 1, 2025 20:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 2,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020849 · form4-08012025_040801.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,813 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 22:56 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 2,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-018798 · form4-07012025_100726.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,382 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 21:01 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 2,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015213 · form4-06022025_090644.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,951 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 8,220 | $5.10 Strike: $5.10 | $41,922.00 |
DisclosureSEC source: 0001415889-25-014467 · form4-05232025_040501.xml · derivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,751 Underlying: Options · 8,220 shares Expires 2027-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $5.10 and an expiration date of June 27, 2027. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 8,220 | $5.10 | $41,922.00 |
DisclosureSEC source: 0001415889-25-014467 · form4-05232025_040501.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $5.10 and an expiration date of June 27, 2027. Read SEC document |
| May 16, 2025 Filed May 19, 2025 20:30 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013641 · form4-05192025_040513.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,300 F1 · security: Represents shares released from restriction from shares awarded 5-16-2024. Read SEC document |
| April 30, 2025 Filed May 1, 2025 22:03 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011688 · form4-05012025_100543.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,633 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 21:17 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009397 · form4-04012025_090441.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,591 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| March 28, 2025 Filed Apr 3, 2025 23:12 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-25-010063 · form4-04032025_110450.xml · derivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 877,722 Underlying: Options · 50,000 shares Expires 2035-03-28 F3 · security: On March 28, 2025, Robert Andrade was granted incentive stock options to purchase 50,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F4 · derivative.exercise_date: One-third of the shares subject to this option may be exercised as of March 28, 2026 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| March 28, 2025 Filed Apr 3, 2025 23:12 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantRestricted Share Unit · Derivative | 75,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010063 · form4-04032025_110450.xml · derivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 827,722 Underlying: Common Shares · 75,000 shares Expires 2035-03-28 F1 · security: On March 28, 2025, Robert Andrade was awarded restricted share units to acquire 75,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan F2 · derivative.exercise_date: One-third of the shares subject to this award shall be released from restriction as of March 28, 2026 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 23:53 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006066 · form4-02282025_110218.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,549 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 22:48 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002785 · form4-02032025_100225.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,507 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:47 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000606 · form4-01032025_100102.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,465 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:09 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028020 · form4-12032024_121202.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,423 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| November 18, 2024 Filed Nov 18, 2024 22:02 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 15,816 | $2.45 Strike: $2.45 | $38,749.20 |
DisclosureSEC source: 0001415889-24-027107 · form4-11182024_101148.xml · derivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 689,184 Underlying: Options · 15,816 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents options granted on July 5, 2016, with a strike price of $2.45 and expiration date of July 5, 2026 Read SEC document |
| November 18, 2024 Filed Nov 18, 2024 22:02 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 15,816 | $2.45 | $38,749.20 |
DisclosureSEC source: 0001415889-24-027107 · form4-11182024_101148.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of option contract with a strike price of $2.45 and an expiration date of July 5, 2026 Read SEC document |
| October 31, 2024 Filed Nov 4, 2024 22:30 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-026038 · form4-11042024_051101.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,565 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:13 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024214 · form4-10012024_091004.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,523 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.